Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Big Data Trends & Strategies for Utilization Across HEOR


Published on

The bio-pharmaceutical industry has been rather slow in embracing Big Data Analytics due to its inherent costs, difficulty in measuring ROI of Big Data, uneven senior management buy-in and other challenges associated with harnessing large sets of information in varied formats. As the industry moves towards recognizing the huge potential that BIG DATA holds for important HEOR decisions, rapid steps are being taken to develop greater BIG DATA capabilities.

Best Practices, LLC undertook this study to probe current & future trends, winning strategies and best practices for Big Data utilization across the HEOR function. The study lprobes the most useful data types and sources for key HEOR decisions; governance policies and leadership and the most meaningful data producers, dissemination channels and targets.

Download Full Report:

Published in: Data & Analytics
  • Be the first to comment

  • Be the first to like this

Big Data Trends & Strategies for Utilization Across HEOR

  1. 1. Big Data in Pharma: Current & Future Trends for Big Data Utilization Across the Health Outcomes Research Function Best Practices, LLC Strategic Benchmarking Research Study with HEOR Functions
  2. 2. 2 Table of Contents I. Executive Summary pp. 3-8  Research Overview pp. 4  Universe of Learning pp. 5-6  Big Data Team Overview and Key Study Insights pp. 7-8  Quantitative Key Findings pp. 9-12 II. Defining Big Data pp. 13-20 III. Data Types and Sources pp. 21-26 IV. Data Producers, Dissemination & Requestors pp. 27-31 V. Centralization pp. 32-34 VI. Governance and Leadership pp. 35-51 VII. About Best Practices, LLC pp. 52
  3. 3. Best Practices, LLC, conducted a customized study – with responses segmented by medical, commercial and Health Outcomes Research (from now on called either Health Outcomes or HEOR) functions - to better understand the growing influence of Big Data in the biopharmaceutical sector and how it impacts HEOR.  Best Practices, LLC engaged 15 leaders from 13 pharmaceutical companies through a benchmarking survey.  Research analysts also conducted seven deep-dive executive interviews with selected benchmark participants. Research Goal Research Methodology  Produce reliable industry metrics on current and future trends for Big Data utilization across medical, commercial and HEOR groups. Topics Covered  Types of Big Data Projects Used to Support Medical, Commercial and HEOR Decisions  Big Data Capabilities and Governance  Types and Value of Data Used for Big Data Projects  Big Data Staffing and Budget Levels  Value Rating of Partnerships on Big Data Projects  Policies and Procedures Governing Big Data Activities  Investigate data types, data partnerships, and staffing/budget levels companies are using as they move to a more analytically based approach to commercial, HEOR & medical decisions. Research Overview Research Project Objectives & Methodology
  4. 4. Benchmark Class: Thirteen Companies Participated in the Benchmark Study Best Practices, LLC engaged 15 leaders from 13 pharmaceutical companies through a benchmarking survey to discuss how their companies approach Big Data utilization within HEOR. Executive interviews were also conducted with function leaders and others from Medical Affairs and Commercial.
  5. 5. Copyright © Best Practices, LLC 5 Analytics Team Big Data Function Understanding Big Data Use in Medical, HEOR & Commercial Decision-Making Big Data Questions • Medical • Commercial • HEOR Big Data Info Types • Electronic Health Records • Government Cost Data • Health Outcomes Big Data Projects • Value Proposition Development • Post-Launch Performance • Real World Studies Big Data Decisions • Go/No Clinical Decisions • ID Market Opportunities • Developing Economic Models/Assessments
  6. 6. Copyright © Best Practices, LLC 6 Quantitative Findings The following key Big Data findings were observed in this study: Only 5 of 36 types of Transactional, Reported, Online, Scientific and Machine- Generated data were rated highly valuable by a majority of study participants. They were: Claims; EHR (Electronic Health Records); Health Outcomes (provider/payer reported); Real World Studies; and Registries. No types of Online or Machine-Generated data were rated highly valuable by a majority of any segment. Six out of ten benchmark participants used post-launch studies around health outcomes. The second most highly rated reported data type is patient reported outcomes data. Half of the study participants said they have a centralized/dedicated group (Big Data team or function) to support Big Data projects. Post-Launch and Customer Segmentation Studies Most Common Big Data Projects Most Have Centralized or Dedicated Big Data Team or Function Only 5 of 36 Types of Data Rated as Highly Valuable
  7. 7. 7 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Health outcomes (provider/ payer reported) Patient reported outcomes (PRO) Government surveys (e.g., NHANES) Internally-driven market research surveys Reported adverse events Call center & customer care Focus groups Impact of Reported/Survey Data (HEOR) Highly impactful Somewhat impactful Not impactful Not used Reported Data: HEOR Highly Values Health Outcomes Data Sixty percent of the study participants in HEOR roles said for Big Data studies they highly value health outcomes data from providers and payers. Patient reported outcomes data was the second highest rated reported data type. N=15 Q: How impactful (or valuable) has each of the following types of reported/survey data sources proven to be?
  8. 8. 8 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Impact of Data Producers (HEOR) Highly impactful Somewhat impactful Not impactful Not used HEOR: Commercial Payers Seen as Most Valuable Data Producers HEOR leaders found commercial payers to be most impactful. HIEs may constitute a larger share of data in the future because of federal payments for participation in data sharing programs. N=15 Q: How impactful (valuable) is each of the following types of data producers?
  9. 9. 9 Division On Centralization Persists for HEOR HEOR leaders split evenly on the question of whether analytics was centralized. Across functions, the industry is still figuring out what Big Data is, who executes it, and where it lives. N=15 Q: Do you have a centralized/ dedicated group of individuals to support Big Data projects? Yes 50% No 50% Dedicated Big Data Team (HEOR)
  10. 10. 10 0% 10% 20% 30% 40% 50% 60% 70% 80% North America EU Europe (nonEU) Asia Big Data Capabilities and Governance by Region (HEOR) Regions with Big Data capabilities Region where governance resides HEOR Reports A 40% Governance Gap in North America HEOR leaders say their Big Data governance is more likely to be based in the EU than North America, but their capabilities are more often in western hemisphere. N=15 Q: Please indicate the regions below where your organization has Big Data capabilities, and where Big Data governance resides.
  11. 11. 11 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Rules about what analysis commercial functions can perform using Big Data Rules about what analysis medical functions can perform with Big Data Rules on Big Data insights-sharing between commercial and medical Rules governing disclosure of findings to public Rules on proactive vs. reactive use of insights from Big Data Rules on disclosure from regulatory perspective Rules on publishing Policies establishing clear ownership for various data types across the company’s information silos Policies and procedures for accessing data (e.g., who can see what) Policies governing protecting identification/ de-identification of patient level data Policies governing clear ownership of IP generated through a partnership Policies regarding review/ approval of research protocols Prevalence of Data Governance Policies (HEOR) HEOR: Majority have Range of Data Governance Policies HEOR leaders reported relatively similar policy frequencies to those reported by medical leaders. N=15 Q: Which of the following policies and procedures are in place at your company to govern Big Data activities?
  12. 12. Copyright © Best Practices, LLC 12 Best Practices, LLC is a research and consulting firm that conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics, and winning strategies of world-class companies. Best Practices, LLC 6350 Quadrangle Drive, Suite 200 Chapel Hill, NC 27517 About Best Practices, LLC